Flutamide-d7 (Synonyms: SCH 13521-d7) |
Katalog-Nr.GC48831
One-Click Copy Product Info
|
Flutamid-d7 ist mit Deuterium bezeichnetes Flutamid.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 223134-72-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Flutamide-d7 is intended for use as an internal standard for the quantification of flutamide by GC- or LC-MS. Flutamide is an androgen receptor antagonist (Kis = 1.3 and 7.5 µM for the cytosolic rat ventral prostate and anterior pituitary receptors, respectively) and prodrug form of 2-hydroxy flutamide .1 Flutamide is converted to 2-hydroxy flutamide by the cytochrome P450 (CYP) isoform CYP1A2 in human liver microsomes.1 It is cytotoxic to PC3 and LNCaP prostate cancer cells with IC50 values of 98.8 and 81.8 µM, respectively.2 Flutamide (50 mg/kg per day) reduces tumor growth in a PC-82 mouse xenograft model.3 Formulations containing flutamide have been used in the treatment of prostate cancer.
1.Shet, M.S., McPhaul, M., Fisher, C.W., et al.Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2Drug Metab. Dispos.25(11)1298-1303(1997) 2.Shi, Q., Wada, K., Ohkoshi, E., et al.Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgensBioorg. Med. Chem.20(13)4020-4031(2012) 3.Nnane, I.P., Long, B.J., Ling, Y.Z., et al.Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: An inhibitor of androgen synthesisBr. J. Cancer83(1)74-82(2000)
| Cas No. | 223134-72-3 | SDF | |
| Überlieferungen | SCH 13521-d7 | ||
| Canonical SMILES | FC(F)(C1=C(C=CC(NC(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)=C1)[N+]([O-])=O)F | ||
| Formula | C11H4D7F3N2O3 | M.Wt | 283.3 |
| Löslichkeit | Methanol: soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5298 mL | 17.6491 mL | 35.2983 mL |
| 5 mM | 706 μL | 3.5298 mL | 7.0597 mL |
| 10 mM | 353 μL | 1.7649 mL | 3.5298 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)